- Home
- PHAR vs ALT Comparison
PHAR vs ALT Comparison
Compare PHAR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ALT
- Stock Information
- Founded
- PHAR 1988
- ALT 1997
- Country
- PHAR Netherlands
- ALT United States
- Employees
- PHAR N/A
- ALT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- ALT Health Care
- Exchange
- PHAR Nasdaq
- ALT Nasdaq
- Market Cap
- PHAR 587.5M
- ALT 472.3M
- IPO Year
- PHAR N/A
- ALT N/A
- Fundamental
- Price
- PHAR $10.03
- ALT $5.59
- Analyst Decision
- PHAR Strong Buy
- ALT Strong Buy
- Analyst Count
- PHAR 3
- ALT 7
- Target Price
- PHAR $30.00
- ALT $21.00
- AVG Volume (30 Days)
- PHAR 3.0K
- ALT 2.0M
- Earning Date
- PHAR 05-08-2025
- ALT 05-13-2025
- Dividend Yield
- PHAR N/A
- ALT N/A
- EPS Growth
- PHAR N/A
- ALT N/A
- EPS
- PHAR N/A
- ALT N/A
- Revenue
- PHAR $320,708,000.00
- ALT $20,000.00
- Revenue This Year
- PHAR $12.39
- ALT N/A
- Revenue Next Year
- PHAR $9.84
- ALT N/A
- P/E Ratio
- PHAR N/A
- ALT N/A
- Revenue Growth
- PHAR 24.13
- ALT N/A
- 52 Week Low
- PHAR $6.65
- ALT $3.55
- 52 Week High
- PHAR $11.07
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- PHAR 71.76
- ALT 56.67
- Support Level
- PHAR $8.60
- ALT $4.95
- Resistance Level
- PHAR $10.28
- ALT $6.05
- Average True Range (ATR)
- PHAR 0.30
- ALT 0.37
- MACD
- PHAR 0.17
- ALT 0.10
- Stochastic Oscillator
- PHAR 88.79
- ALT 65.67
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.